Immunovant, Inc. shares rose 20% on Wednesday after positive preliminary results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis.
The company reported ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% at Week 16.
The trial enrolled 170 patients who had failed two or more prior advanced therapies. At completion, 165 were evaluable.
IMVT-1402 was safe and well-tolerated, with no new safety signals. Immunovant plans further updates in H2 2026.
